Abnormally High Levels of Brain N-Acetylaspartate in Children with Sickle Cell Disease

References

1. ↵
   Martin E, Capone A, Schneider J, Hennig J, Thiel T. Absence of N-acetylaspartate in the human brain: impact on neurospectroscopy? Ann Neurol 2001;49:518–521

   CrossRefPubMedWeb of Science
2. ↵
   Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23–31

   CrossRefPubMedWeb of Science
3. ↵
   Meyerhoff DJ, MacKay S, Bachman L, et al. Reduced brain N-acetyl-aspartate suggests neuronal loss in cognitively impaired human immuno-deficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging. Neurology 1993;43:509–515

   Abstract/FREE Full Text
4. ↵
   Zimmerman RA, Wang ZJ. The value of proton MR spectroscopy in pediatric metabolic brain disease. AJNR Am J Neuroradiol 1997;18:1872–1879

   PubMedWeb of Science
5. ↵
   Taylor JS, Ogg RJ, Langston JW. Proton MR spectroscopy of pediatric brain tumors. Neuroimag Clin N Am 1998;8:753–779
6. ↵
   Taylor DL, Davies SEC, Obrenovitch TP, et al. Investigation into the role of N-acetylaspartate in cerebral osmoregulation. J Neurochem 1995;65:275–281

   PubMedWeb of Science
7. ↵
   Baslow MH. Evidence supporting a role for N-acetyl-L-aspartate as a molecular water pump in myelinated neurons in the central nervous system: an analytical review. Neurochem. Int 2002;40:295–300

   CrossRefPubMedWeb of Science
8. ↵
   Wang Z, Bogdan AR, Zimmerman R, Gusnard DA, Leigh JS, Ohene-Frempong K. Investigation of stroke in sickle cell disease by ¹H nuclear magnetic resonance spectroscopy. Neuroradiology 1992;35:57–65

   CrossRefPubMed
9. ↵
   Steen RG, Emudianughe T, Hankins G, et al. Brain imaging findings in pediatric sickle cell disease patients. Radiology 2003;228:216–225

   CrossRefPubMedWeb of Science
10. ↵
    Glass JO, Reddick WE, Goloubeva O, Yo V, Steen RG. Hybrid artificial neural network segmentation of precise and accurate inversion recovery (PAIR) images from normal human brain. Magn Reson Imaging 2000;18:1245–1253

    CrossRefPubMed
11. ↵
    Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci 1987;508:333–348

    CrossRefPubMedWeb of Science
12. ↵
    Ogg RJ, Kingsley PB, Taylor JS. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy. J Magn Reson B 1994;104:1–10

    CrossRefPubMedWeb of Science
13. ↵
    Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HBW. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imaging 1992;11:107–118
14. ↵
    Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson. Med 1993;30:672–679

    CrossRefPubMedWeb of Science
15. ↵
    Olson DP, Hirashima F, Yurgelun-Todd DA, Renshaw PF. Relaxation effects in quantitative MRS in schizophrenia. In: Nasrallah HA, Delisi LE, eds. International Congress of Schizophrenia Research. Colorado Springs: Schizophrenia Research;2003 :244
16. ↵
    Ke Y, Coyle JT, Simpson NS, Gruber SA, Renshaw PF, Yurgelun-Todd DA. Frontal brain NAA T2 values are significantly lower in schizophrenia. In: Nasrallah HA, Delisi LE, eds. International Conference on Schizophrenia Research. Colorado Springs: Schizophrenia Research;2003 :242
17. ↵
    Whittall KP, MacKay AL, Graeb DA, Nugent RA, Li DKB, Paty DW. In vivo measurement of T2 distributions and water contents in normal human brain. Magn Reson Med 1997;37:34–43

    CrossRefPubMedWeb of Science
18. ↵
    Kreis R, Ernst T, Ross BD. Absolute quantitation of water and metabolites in the human brain, II: metabolite concentrations. J Magn Reson B 1993;102:9–19

    CrossRefWeb of Science
19. ↵
    de Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721–727

    PubMedWeb of Science
20. ↵
    Shimizu H, Shirane R, Fujiwara S, Takahashi A, Yoshimoto T. Proton magnetic resonance spectroscopy in children with moya-moya disease. Clin Neurol Neurosurg 1997;99:S64–S67
21. ↵
    Kalra S, Cashman NR, Genge A, Arnold DL. Recovery of N-acetylaspartate in corticomotor neurons of patients with ALS after riluzole therapy. Neuroreport 1998;9:1757–1761

    PubMedWeb of Science
22. ↵
    Mascalchi M, Belli G, Guerrini L, Nistri M, Del Sappia I, Vallari N. Proton MR spectroscopy of Wernicke encephalopathy. AJNR Am J Neuroradiol 2002;23:1803–1806

    Abstract/FREE Full Text
23. ↵
    Grodd W, Krageloh-Mann I, Petersen D, Trefz FK, Harzer K. In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan’s disease) by proton spectroscopy. Lancet 1990;336:437–438

    PubMedWeb of Science
24. ↵
    Takanashi J, Inoue K, Tomita M, Kurihara A, Morita F, Ikehira H, et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002;58:237–241

    Abstract/FREE Full Text
25. ↵
    Deicken RF, Eliaz Y, Feiwell R, Schuff N. Increased thalamic N-acetylaspartate in male patients with familial bipolar I disorder. Psychiatr Res Neuroimag 2001;106:35–45
26. ↵
    Barker PB. N-acetyl aspartate-a neuronal maker? Ann Neurol 2001;49:423–424

    CrossRefPubMedWeb of Science
27. ↵
    Steen RG, Xiong X, Mulhern RK, Langston JW, Wang WC. Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. Ann Neurol 1999;45:279–286

    CrossRefPubMedWeb of Science